Actualités et vidéos - MIRATI THERAPEUTICS INC.

European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland, Jan. 10, 2024 SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the European Commission (EC) granted conditional marketing authorization for KRAZATI ® ( adagrasib ) as...

Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure PR Newswire SAN DIEGO, Calif. and ZUG, Switzerland, Nov. 10, 2023 SAN DIEGO, Calif. and ZUG, Switzerland , Nov. 10, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that following a...

Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates PR Newswire SAN DIEGO, Nov. 6, 2023 SAN DIEGO , Nov. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the third quarter 2023 along with recent pipeline and corporate updates. "We are pleased to share the significant progress made during the third quarter of 2023, highlighted by the advancement of our...

Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland, Nov. 3, 2023 SAN DIEGO and ZUG, Switzerland , Nov. 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) granted...

Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC) PR Newswire SAN DIEGO, Oct. 17, 2023 SAN DIEGO , Oct. 17, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced updated results from the KRYSTAL-7 Phase 2 study evaluating adagrasib combined with pembrolizumab in patients for the treatment of first-line NSCLC harboring a KRAS G12C...

Shareholder Alert: Ademi LLP investigates whether Mirati Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol Myers Squibb PR Newswire MILWAUKEE, Oct. 9, 2023 MILWAUKEE , Oct. 9, 2023 /PRNewswire/ -- Ademi LLP is investigating Mirati (Nasdaq: MRTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Bristol Myers Squibb . Click here to learn how to join the action https://www.ademilaw.com/case/mirati-therapeutics-inc or call Guri...

Mirati To Present Updated Clinical Data at ESMO Congress 2023 PR Newswire SAN DIEGO, Sept. 27, 2023 Late-Breaking KRYSTAL-7 data demonstrates compelling efficacy and safety of adagrasib in combination with pembrolizumab in 1L NSCLC Data follows recent inclusion of the adagrasib in combination with an EGFR inhibitor listed in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Colon and Rectal Cancers SAN DIEGO , Sept. 27, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc....

Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer PR Newswire SAN DIEGO, Sept. 9, 2023 SAN DIEGO , Sept. 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage research and development, biotechnology company, today presented two-year follow-up data from a pooled analysis of the Phase 1/ 1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating...

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, Sept. 5, 2023 SAN DIEGO , Sept. 5, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the company granted equity awards to 3 new employees with a grant date of September 1, 2023 , as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan)...

Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer PR Newswire SAN DIEGO, Aug. 23, 2023 SAN DIEGO , Aug. 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that Laurie Stelzer , Chief Financial Officer, will depart the company on September 8, 2023 , to pursue an external opportunity. Aaron Ondrey , senior vice president, financial planning and analysis (FP&A), Mirati Therapeutics, will...

Mirati To Present Pooled Clinical Data from Adagrasib's KRYSTAL-1 Study Demonstrating Overall Survival Results at Two-Years of Follow-Up at 2023 World Conference on Lung Cancer PR Newswire SAN DIEGO, Aug. 21, 2023 SAN DIEGO , Aug. 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced a presentation of two-year follow-up from a pooled analysis of the Phase 1/ 1b Cohort and Phase 2 Cohort A for the KRYSTAL-1 study evaluating...

Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire SAN DIEGO, Aug. 11, 2023 SAN DIEGO , Aug. 11, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a commercial stage biotechnology company, today announced the closing of its previously announced underwritten public offering of 11,288,336 shares of its common stock at a price to the public of $27.80 per share, and, to certain investors,...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mirati Therapeutics, Inc. - MRTX PR Newswire NEW YORK, Aug. 10, 2023 NEW YORK , Aug. 10, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc . ("Mirati" or the "Company") (NASDAQ: MRTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Mirati and certain of its...

Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition PR Newswire SAN DIEGO, Aug. 9, 2023 The detailed pharmacological and mechanistic characterization of MRTX1719 demonstrates that blocking PRMT5-MTA complex is a rational and differentiated approach to treat cancers harboring MTAP deletion Partial responses observed in patients with advanced cancer along with a well-tolerated safety...

Mirati Therapeutics Announces Pricing of Upsized Public Offering PR Newswire SAN DIEGO, Aug. 8, 2023 SAN DIEGO , Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a commercial stage biotechnology company, today announced the pricing of an underwritten public offering of 9,669,631 shares of its common stock at a price to the public of $27.80 per share, and, to certain investors, pre-funded warrants to purchase 1,121,736 shares of common stock at a price of $27.799 per...

Mirati Therapeutics Announces Proposed Public Offering PR Newswire SAN DIEGO, Aug. 8, 2023 SAN DIEGO , Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a commercial stage biotechnology company, today announced that it intends to offer and sell $250.0 million of shares of its common stock, and, to certain investors, pre-funded warrants to purchase shares of common stock, in an underwritten public offering. The purchase price of each pre-funded warrant will equal the price...

Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates PR Newswire SAN DIEGO, Aug. 8, 2023 Shares plans to initiate Phase 3 combination study evaluating adagrasib with pembrolizumab in first line non-small cell lung cancer in patients with TPS ≥ 50% Announces compelling initial clinical data for MRTX1719 in MTAP-deleted cancers demonstrating favorable safety profile and early signs of strong clinical activity David Meek to depart Company, Charles M. Baum...

Mirati Therapeutics Announces Departure of Chief Executive Officer David Meek PR Newswire SAN DIEGO, Aug. 8, 2023 Charles M. Baum , M.D., Ph.D. assumes role of interim CEO SAN DIEGO , Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company today announced that David Meek and the Company mutually agreed for Mr. Meek to step down from his role as CEO and as a member of the Board of Directors. His responsibilities have been assumed by...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mirati Therapeutics, Inc. - MRTX PR Newswire NEW YORK, Aug. 4, 2023 NEW YORK , Aug. 4, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mirati Therapeutics, Inc . ("Mirati" or the "Company") (NASDAQ: MRTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Mirati and certain of its...

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) PR Newswire SAN DIEGO, Aug. 3, 2023 SAN DIEGO , Aug. 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that the company granted equity awards to a new employee with a grant date of August 1, 2023 , as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and...